Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166823 | 0.89 | FBP1 (0.42) | FBP1HCRTR2GSK3BHCRTR1CARM1 | |
| SCHEMBL1167752 | 0.89 | HCRTR2 (0.45) | FBP1HCRTR2GSK3BHCRTR1CARM1 | |
| SCHEMBL1167066 | 0.80 | GSK3B (0.53) | FBP1HCRTR2GSK3BHCRTR1 | |
| SCHEMBL1166258 | 0.77 | ADRB2 (0.46) | FBP1HCRTR2GSK3BHCRTR1CARM1 | |
| SCHEMBL1166792 | 0.76 | GSK3B (0.51) | FBP1HCRTR2GSK3BHCRTR1ADORA2A | |
| SCHEMBL1166864 | 0.76 | CYP4F2 (0.52) | FBP1HCRTR2GSK3BHCRTR1ADORA2A | |
| SCHEMBL1166205 | 0.74 | GSK3B (0.43) | FBP1HCRTR2GSK3BHCRTR1 | |
| SCHEMBL27832921 | 0.74 | CARM1 (0.33) | HCRTR2HCRTR1CARM1 | |
| SCHEMBL1166876 | 0.73 | GSK3B (0.50) | FBP1HCRTR2GSK3BHCRTR1ADORA2A | |
| SCHEMBL5474080 | 0.72 | LOXL2 (0.51) | FBP1HCRTR2GSK3BHCRTR1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
| CN-101903353-A | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | FBP1 1879/4885HCRTR2 2700/4885GSK3B 2540/4885 |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | FBP1 1975/4885HCRTR2 55/4885GSK3B 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.